Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro Inc (ALZN) is a clinical-stage biopharmaceutical company advancing novel treatments for neurodegenerative and psychiatric disorders. This news hub provides investors and researchers with essential updates on therapeutic developments, regulatory progress, and scientific breakthroughs.
Access timely announcements about ALZN's pipeline candidates: AL001 (ionic cocrystal lithium therapy) and AL002 (immunotherapeutic Alzheimer's vaccine). Track press releases covering clinical trial phases, partnership agreements, intellectual property developments, and financial disclosures.
Our curated news collection serves as a centralized resource for monitoring ALZN milestones in Alzheimer's research, bipolar disorder treatment innovations, and neurotherapeutic advancements. Bookmark this page for verified updates on FDA communications, peer-reviewed study publications, and strategic corporate decisions.
Alzamend Neuro (NASDAQ: ALZN) has announced a 1-for-9 reverse stock split effective May 12, 2025. The clinical-stage biopharmaceutical company, focused on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD, implemented this measure primarily to maintain Nasdaq listing compliance with the minimum bid requirement of $1.00 per share.
The company's outstanding shares will decrease from approximately 7,208,591 to 800,954 shares. The stock will continue trading under the symbol "ALZN" with a new CUSIP number 02262M605. While the split affects all issued and outstanding shares, including equity incentive plans and outstanding options/warrants, it won't alter stockholders' percentage ownership. Stockholders entitled to fractional shares will receive cash payments instead.
Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate a Phase II clinical trial of AL001 for Alzheimer's disease treatment in Q4 2025 at Massachusetts General Hospital. The study follows the successful completion of a head coil by Tesla Dynamic Coils BV.
The trial will compare AL001 with marketed lithium carbonate, focusing on lithium blood and brain pharmacokinetics in Alzheimer's patients. Previous mouse studies showed AL001 achieves better brain absorption while maintaining lower blood lithium levels, potentially eliminating the need for therapeutic drug monitoring (TDM).
The company previously completed a Phase IIA multiple-ascending dose study, establishing a maximum tolerated dose that likely won't require TDM while providing effective lithium dosing. AL001 is designed to improve lithium distribution in the brain while reducing exposure to other organs, potentially offering a safer profile compared to current lithium salts.
Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate a Phase II clinical trial of AL001 for Major Depressive Disorder (MDD) treatment in Q4 2025 at Massachusetts General Hospital. The study follows the successful completion of a head coil by Tesla Dynamic Coils BV.
The trial will compare AL001 with marketed lithium carbonate, focusing on lithium blood and brain pharmacokinetics in MDD patients. Previous mouse studies showed AL001 achieves better brain absorption while maintaining lower blood lithium levels, potentially eliminating the need for therapeutic drug monitoring (TDM).
AL001 aims to overcome limitations of current FDA-approved lithium salts, which require regular monitoring due to a narrow therapeutic window. While lithium lacks FDA approval for MDD treatment, it has been prescribed off-label for decades as an antidepressant augmentation therapy, showing efficacy in multiple randomized controlled trials.
Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate a Phase II clinical study of AL001 for treating post-traumatic stress disorder (PTSD) in Q4 2025. The trial, to be conducted at Massachusetts General Hospital, will compare AL001 with marketed lithium carbonate to evaluate lithium blood and brain pharmacokinetics in PTSD subjects.
The study follows the successful completion of a head coil by Tesla Dynamic Coils BV. Previous mouse studies demonstrated AL001's superior brain absorption while maintaining lower blood lithium levels, potentially eliminating the need for therapeutic drug monitoring (TDM). While lithium lacks FDA approval for PTSD, case reports suggest effectiveness at low doses (300-600 mg/day) in reducing anger, irritability, anxiety, and insomnia in PTSD patients.
The development aims to overcome limitations of current FDA-approved lithium salts, which require regular monitoring due to a narrow therapeutic window. This advancement could benefit over 9 million Americans with PTSD by offering a more effective treatment option with enhanced safety and better brain targeting.
Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate a Phase II clinical trial for AL001 in treating Bipolar Disorder (BD) in Q3 2025. The study, to be conducted at Massachusetts General Hospital, will compare AL001 with marketed lithium carbonate, focusing on lithium blood and brain pharmacokinetics.
The trial follows the successful completion of a head coil by Tesla Dynamic Coils BV. Previous mouse studies showed AL001 achieves better brain absorption while maintaining lower blood lithium levels. The novel formulation aims to eliminate the need for lithium therapeutic drug monitoring (TDM), addressing limitations of current FDA-approved lithium salts that require regular monitoring due to narrow therapeutic windows.
AL001's potential advantages include enhanced safety, improved brain targeting, and reduced systemic side effects, particularly regarding kidney and thyroid complications commonly associated with traditional lithium therapies. This advancement could benefit over 7 million Americans with BD by offering a more effective treatment option.
Alzamend Neuro (NASDAQ: ALZN) has announced plans to initiate the first of five phase II clinical studies for AL001 in the second quarter of 2025. The initial study will be conducted at Massachusetts General Hospital with healthy human subjects following the successful development of a novel head coil by Tesla Dynamic Coils BV.
This head-to-head study will compare AL001 with marketed lithium carbonate products, focusing on lithium blood and brain pharmacokinetics. Previous mouse studies showed AL001 provides better brain absorption while maintaining lower blood lithium levels, potentially eliminating the need for therapeutic drug monitoring (TDM).
AL001 aims to overcome limitations of current FDA-approved lithium salts (carbonate and citrate), which require regular monitoring due to narrow therapeutic windows and multiple daily doses. The novel formulation could represent a significant advancement in treating Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD by reducing kidney and thyroid side effects associated with traditional lithium therapies.
Alzamend Neuro (NASDAQ: ALZN) announced the completion of a groundbreaking head coil by Tesla Dynamic Coils BV, essential for five upcoming Phase II clinical trials. The trials, conducted at Massachusetts General Hospital, will compare AL001 versus marketed lithium carbonate in healthy individuals and patients with Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
The specialized head coil enables whole-brain imaging of lithium with high resolution, allowing precise quantification within brain structures. Previous nonclinical studies showed AL001 optimizes brain absorption with lower blood concentration levels compared to lithium carbonate. This innovation could potentially eliminate the need for lithium therapeutic drug monitoring while providing safer dosing options and expanding the therapeutic index.
Alzamend Neuro (NASDAQ: ALZN), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming Sequire Investor Summit from January 21-23, 2025, at the Condado Vanderbilt in Puerto Rico. CEO Stephan Jackman will present on January 22, 2025, at 11:30 a.m. ET.
The presentation will highlight the company's improved financial position and plans for five Phase II trials of AL001 to be initiated in 2025 in partnership with Massachusetts General Hospital. The company focuses on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.
The Sequire Investor Summit, in its third edition, will feature 75+ presenting companies and host over 500 investors, funds, family offices, and analysts. Registration is mandatory for attendance through the provided link.
Alzamend Neuro (NASDAQ: ALZN) announced its upcoming poster presentation at the Society of Toxicology Annual Meeting in March 2025, featuring non-clinical data on AL001, a lithium-based treatment. The presentation will showcase comparative data between AL001 and lithium carbonate in Alzheimer's transgenic mice. Key findings demonstrate AL001's enhanced brain-specific lithium delivery with minimized systemic exposure, showing no adverse effects while maintaining higher brain lithium concentrations at lower doses compared to lithium carbonate.
Following successful Phase I and IIA trials, Alzamend plans five Phase II trials in partnership with Massachusetts General Hospital in 2025, targeting treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company aims to pursue FDA 505(b)(2) approval pathway for AL001.
FAQ
What is the current stock price of Alzamend Neuro (ALZN)?
What is the market cap of Alzamend Neuro (ALZN)?
